11/26/13 Mizuho Securities maintained a BUY rating on Questcor Pharmaceuticals (NASDAQ: QCOR) with a price target of $93.00. Comments follow negative coverage by Citron Research and concerns about a possible investigation by the FTC.
Analyst Mario Corso said Questcor hasn’t received a formal FTC inquiry regarding its deal to acquire Synacthen, and anything informal may have been a response to updated HSR guidelines. So far Questcor isn’t indicating if it did or didn’t receive an informal inquiry. However, if it did occur, it wouldn’t preclude a deal for Synacthen near-term. In addition, if the FTC pursues a court challenge it may take more than 2 years to decide.
Shesh.. bumping this, really? Do you not know what is going on here? These analysts mean nothing right now... Analysts are full of it. Pick your favorite and actually track what they spew... After a years time has past, you will see the value of the so called pumper analysts..
BUMP! Stock is bringing in too much REVENUE! Shorts do not get this. They are setting themselves up when they are the last ones left shorting. WATCH OUT FOR THE NEXT SQUEEZE IN THE MAKINGS. PLEASE KEEP SHORTING THE MORE THE BETTER!
Sentiment: Strong Buy
Multiple sources have confirmed to The Capitol Forum that the FTC has launched a nonpublic investigation into Questcor's acquisition of the U.S. rights to Synacthen. Unlike previous investigations into non-reportable pharmaceutical transactions , which have taken two years or longer , we believe that the FTC investigation will move according to an accelerated timeline. As a result, an FTC decision, either to close its investigation or move to unwind the deal , could come within months, not years. Key points for shareholders to consider include:
Investigation . Multiple sources have confirmed that the FTC has initiated an investigation into Questcor's acquisition of the U.S. rights to Synacthen.
Political pressure. On August 1, Senator Amy Klobuchar, chair of the Senate's antitrust subcommittee , sent a letter to FTC chairwoman Edith Ramirez encouraging the Commission to investigate the deal.
Timing. Given political pressure, public/investor interest , and concern about the effects of a delay of Synacthen's entry into the U.S. market , the timeline of the FTC's investigation may be months, not years. Less